Completed PHASE4 INTERVENTIONAL 2-arm NCT00253266

Venlafaxine Augmentation in Treatment Resistant Depression

Comparison of Venlafaxine Augmentation With Quetiapine v.s. Placebo in Treatment Resistant Depression

Sponsor: Max-Planck-Institute of Psychiatry

Updated 5 times since 2017 Last updated: Apr 7, 2015 Started: Apr 30, 2008 Primary completion: Apr 30, 2014 Completion: Aug 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Depression and is currently completed. Max-Planck-Institute of Psychiatry leads this study, which shows 5 recorded versions since 2008 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Apr 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Max-Planck-Institute of Psychiatry

Data source: Max-Planck-Institute of Psychiatry

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Munich, Germany